End-of-day quote
Shenzhen S.E.
18:00:00 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
16.04
CNY
|
-5.48%
|
|
-8.66%
|
-19.56%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6,630
|
6,321
|
3,151
|
4,591
|
5,093
|
19,272
|
Enterprise Value (EV)
1 |
6,912
|
7,401
|
4,745
|
6,142
|
6,554
|
20,796
|
P/E ratio
|
20.2
x
|
-3.1
x
|
-8.81
x
|
119
x
|
176
x
|
399
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.17
x
|
3.2
x
|
2.83
x
|
3.03
x
|
3.46
x
|
13.1
x
|
EV / Revenue
|
3.3
x
|
3.74
x
|
4.27
x
|
4.05
x
|
4.46
x
|
14.1
x
|
EV / EBITDA
|
21.3
x
|
64.9
x
|
-17
x
|
33.8
x
|
33.1
x
|
95.3
x
|
EV / FCF
|
285
x
|
-557
x
|
56.9
x
|
54.8
x
|
65.6
x
|
221
x
|
FCF Yield
|
0.35%
|
-0.18%
|
1.76%
|
1.83%
|
1.52%
|
0.45%
|
Price to Book
|
1.41
x
|
2.4
x
|
1.39
x
|
1.99
x
|
2.18
x
|
5.31
x
|
Nbr of stocks (in thousands)
|
966,495
|
966,495
|
966,495
|
966,495
|
966,495
|
966,495
|
Reference price
2 |
6.860
|
6.540
|
3.260
|
4.750
|
5.270
|
19.94
|
Announcement Date
|
19-04-09
|
20-04-28
|
21-04-26
|
22-04-18
|
23-04-18
|
24-04-18
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,095
|
1,977
|
1,112
|
1,515
|
1,471
|
1,473
|
EBITDA
1 |
324.1
|
114
|
-278.7
|
181.5
|
198.2
|
218.1
|
EBIT
1 |
257.3
|
46.27
|
-346.2
|
112.5
|
127
|
143.4
|
Operating Margin
|
12.28%
|
2.34%
|
-31.14%
|
7.43%
|
8.64%
|
9.73%
|
Earnings before Tax (EBT)
1 |
409.2
|
-2,013
|
-355.8
|
59.62
|
50.17
|
54.86
|
Net income
1 |
330.9
|
-2,042
|
-359.5
|
35.27
|
30.15
|
43.93
|
Net margin
|
15.8%
|
-103.27%
|
-32.33%
|
2.33%
|
2.05%
|
2.98%
|
EPS
2 |
0.3400
|
-2.113
|
-0.3700
|
0.0400
|
0.0300
|
0.0500
|
Free Cash Flow
1 |
24.23
|
-13.29
|
83.36
|
112.2
|
99.93
|
94.21
|
FCF margin
|
1.16%
|
-0.67%
|
7.5%
|
7.4%
|
6.79%
|
6.39%
|
FCF Conversion (EBITDA)
|
7.48%
|
-
|
-
|
61.79%
|
50.42%
|
43.19%
|
FCF Conversion (Net income)
|
7.32%
|
-
|
-
|
317.99%
|
331.42%
|
214.45%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-04-09
|
20-04-28
|
21-04-26
|
22-04-18
|
23-04-18
|
24-04-18
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
282
|
1,080
|
1,594
|
1,551
|
1,461
|
1,524
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.87
x
|
9.472
x
|
-5.72
x
|
8.545
x
|
7.372
x
|
6.986
x
|
Free Cash Flow
1 |
24.2
|
-13.3
|
83.4
|
112
|
99.9
|
94.2
|
ROE (net income / shareholders' equity)
|
7.18%
|
-55.1%
|
-14.5%
|
1.46%
|
1.24%
|
1.84%
|
ROA (Net income/ Total Assets)
|
2.74%
|
0.54%
|
-4.47%
|
1.46%
|
1.7%
|
1.95%
|
Assets
1 |
12,062
|
-377,638
|
8,036
|
2,412
|
1,771
|
2,256
|
Book Value Per Share
2 |
4.870
|
2.720
|
2.350
|
2.390
|
2.420
|
3.760
|
Cash Flow per Share
2 |
0.3300
|
0.2900
|
0.5300
|
0.3100
|
0.3500
|
0.2900
|
Capex
1 |
74.4
|
61
|
19.2
|
25.5
|
23.7
|
26.7
|
Capex / Sales
|
3.55%
|
3.08%
|
1.72%
|
1.68%
|
1.61%
|
1.81%
|
Announcement Date
|
19-04-09
|
20-04-28
|
21-04-26
|
22-04-18
|
23-04-18
|
24-04-18
|
|
1st Jan change
|
Capi.
|
---|
| -19.56% | 2.27B | | +31.06% | 682B | | +30.35% | 586B | | -3.42% | 364B | | +18.02% | 327B | | +4.27% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +8.12% | 165B |
Other Pharmaceuticals
|